BCMA/CD3e tri-specific T-cell activating construct HPN217

{
  "id": "MLC-T-ONC-011913",
  "term": "BCMA/CD3e tri-specific T-cell activating construct HPN217",
  "field": "Oncology and biomedicine",
  "definition": "A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; TNFRSF17), the epsilon domain of CD3 antigen (CD3e) found on T lymphocytes, and albumin, with potential immunostimulating and antineoplastic activities. Upon administration, BCMA/CD3e TriTAC HPN217 targets and binds to BCMA on tumor cells and CD3e on cytotoxic T lymphocytes (CTLs), thereby bringing BCMA-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN217. BCMA, a member of the tumor necrosis factor receptor superfamily (TNFRSF), is overexpressed on malignant plasma cells and plays a key role in plasma cell survival.",
  "synonyms": [
    "anti-BCMA/CD3e TriTAC HPN217",
    "BCMA/CD3 tri-specific T-cell activating construct HPN217",
    "BCMA/CD3e TriTAC HPN217",
    "BCMA/CD3e-specific TriTAC HPN217",
    "TriTAC HPN217"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/bcma-cd3e-tri-specific-t-cell-activating-construct-hpn217/"
}